New anti-clotting medication reduces bleeding among people with atrial fibrillation
NewMediaWire·Heart chambers illustration
NewMediaWire
6 min read
Research Highlights:
Bleeding was reduced by more than 60% among people taking the anti-clotting agent abelacimab, demonstrating its safety for people at risk of stroke from atrial fibrillation.
Abelacimab was compared with another standard-of-care anti-clotting medication rivaroxaban for occurrence of bleeding in a study of more than 1,200 people at moderate to high risk of stroke from an irregular heart rhythm.
The trial was stopped early in September 2023 due to a "overwhelming reduction" in bleeding with abelacimab.
Embargoed until 8:15 a.m. ET, Sunday, Nov. 12, 2023
(NewMediaWire) - November 12, 2023 - PHILADELPHIA An experimental anti-clotting medication, abelacimab, significantly reduced bleeding among people with atrial fibrillation (or AFib) who were at risk of stroke, according to results of the AZALEA-TIMI 71 trial, presented today as late-breaking science at the American Heart Association's Scientific Sessions 2023. The meeting, Nov. 11-13, in Philadelphia, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
"This trial confirms the promise of abelacimab to be an incredibly safe anticoagulant for stroke prevention in people with AFib," said study author Christian T. Ruff, M.D., M.P.H., director of general cardiology at Brigham and Women's Hospital in Boston, senior investigator for the TIMI Group and an associate professor of medicine at Harvard Medical School.
The AZALEA-TIMI 71 trial was stopped prematurely on the recommendation of the independent Data Monitoring Committee in September 2023 due to an "overwhelming reduction" in bleeding with abelacimab compared to the anti-clotting medication rivaroxaban.
This is the initial, topline analysis of the Phase 2 of the multi-national trial that compared bleeding occurrence in 1,287 people taking either 90 mg or 150 mg of abelacimab (a factor XI inhibitor) via monthly injection versus people taking 20 mg daily of the oral anti-clotting medication or anticoagulant rivaroxaban. It is the longest and largest trial to-date comparing factor XI inhibitors to the current standard of care use of direct-acting oral anticoagulants.
The analysis found that abelacimab substantially reduced bleeding among people with AFib compared with rivaroxaban, specifically:
Abelacimab reduced major bleeding that usually required hospitalization and bleeding that required medical attention but not hospitalization by 67% at a dose of 150 mg and 77% at a dose of 90 mg, compared to rivaroxaban.
At a dose of 150 mg, abelacimab reduced major bleeding by 74% compared to rivaroxaban; and at a dose of 90 mg, it reduced major bleeding by 81%.
Both doses of abelacimab reduced gastrointestinal bleeding by 93% compared to rivaroxaban.
Abelacimab was well tolerated with similar rates of adverse events compared with rivaroxaban.
"Assuming the data from ongoing phase 3 trials confirm the benefit of factor XI inhibitors for stroke prevention in people with atrial fibrillation, it will really be transformative for the field of cardiology," Ruff said. "Our first mission in treating people with AFib is to prevent stroke, and our ability to do this with a remarkably safe anticoagulant such as abelacimab would be an incredible advance."
People with AFib have about five times higher risk of stroke than people without the irregular heart rhythm condition, according to the American Heart Association. Typically, health care professionals will prescribe blood thinners or anticoagulants to reduce the risk of stroke by restricting the body's ability to form blood clots, Ruff said. However, anti-clotting medications include a higher risk for bleeding, which may also be life threatening or result in patients discontinuing treatment, and therefore these issues influence who may safely take anti-coagulants.
Trial details and background:
Abelacimab is an injectable, monoclonal antibody, categorized as a factor XI inhibitor, that has the potential to prevent the clots that cause strokes and heart attacks while preserving the body's natural ability to repair blood vessels during an injury. This could lower the risk of bleeding for people who take it.
The study enrolled 1,287 adults across 95 global study sites including the U.S. and Canada, Europe and Asia between March and December 2021 with median follow-up of 1.8 years.
Participants were 55-years-old and older (44% women) with a history of AFib and who were taking anticoagulants.
Participants were at moderate to high risk of stroke as determined by history of congestive heart failure, high blood pressure, their age, Type 2 diabetes and stroke and vascular disease which is known as the CHA2DS2-VASc score.
In a 2021 study, abelacimab was shown to effectively prevent blood clots among people who had knee replacement surgery.
Co-authors, disclosures and funding sources are listed in the abstract.
Statements and conclusions of studies that are presented at the American Heart Association's scientific meetings are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association's scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association's overall financial information are available here.
For more news at AHA Scientific Sessions 2023, follow us on X (formerly known as Twitter) @HeartNews,#AHA23
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public's health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.
